SEC14L2/TAP抗体;SEC14L2/TAP Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of SEC14L2 / TAP expression in U87-MG cell lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:150 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

SEC14L2/TAP (SEC14-like protein 2/Target of Atorvastatin-induced Phosphoprotein) is a member of the SEC14 family of lipid-binding proteins, characterized by a conserved SEC14 domain that facilitates interactions with lipids and cellular membranes. Encoded by the SEC14L2 gene, this protein is predominantly expressed in the liver and gastrointestinal tract, where it plays roles in lipid metabolism, intracellular vesicular trafficking, and membrane dynamics. TAP was initially identified as a target phosphorylated in response to atorvastatin, a cholesterol-lowering drug, linking it to cholesterol homeostasis and lipoprotein assembly pathways.

Research suggests SEC14L2/TAP regulates hepatic very-low-density lipoprotein (VLDL) secretion by influencing lipid droplet formation and apolipoprotein B stability. Dysregulation of SEC14L2/TAP has been implicated in metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), hepatitis, and hepatocellular carcinoma. Its expression is modulated by nutritional status, insulin signaling, and oxidative stress, highlighting its sensitivity to metabolic cues.

SEC14L2/TAP antibodies are critical tools for studying its localization, expression patterns, and molecular interactions. They enable detection in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies have also been used to explore SEC14L2/TAP’s role in disease contexts, such as its downregulation in liver fibrosis or its potential as a biomarker for statin-induced metabolic changes. Ongoing studies aim to clarify its exact mechanisms in lipid trafficking and its therapeutic relevance in metabolic and liver-related pathologies.